Clinical Trial Update: S1313, PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic Cancer [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for S1313 evaluating PEGPH20 in newly diagnosed metastatic pancreatic cancer (Phase 1/2) has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Adenocarcinoma
• Pancreatic Cancer

Drugs mentioned

• PEGPH20 (pegylated hyaluronidase)

Snippet

Sponsor: SWOG Cancer Research Network | Conditions: Metastatic Pancreatic Adenocarcinoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2020-02-12